Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Alaunos Therapeutics, Inc. (ZIOP) since 2015 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Alaunos Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1107421.
Total stock buying since 2015: $13,289,206.
Total stock sales since 2015: $5,142,616.
Total stock option exercises since 2015: $1,668,555.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2023 | 0 | $0 | 68,014 | $9,521 | 0 | $0 |
| 2021 | 358,770 | $639,084 | 219,859 | $596,191 | 0 | $0 |
| 2020 | 0 | $0 | 113,630 | $517,014 | 0 | $0 |
| 2019 | 0 | $0 | 122,361 | $601,437 | 71,309 | $143,748 |
| 2017 | 10,710 | $50,122 | 0 | $0 | 140,000 | $509,400 |
| 2016 | 0 | $0 | 0 | $0 | 75,000 | $397,950 |
| 2015 | 1,440,000 | $12,600,000 | 300,833 | $3,418,453 | 234,167 | $617,457 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2023-09 | 0 | $0 | 68,014 | $9,521 | 0 | $0 |
| 2021-12 | 0 | $0 | 20,132 | $25,567 | 0 | $0 |
| 2021-11 | 10,000 | $13,999 | 0 | $0 | 0 | $0 |
| 2021-09 | 348,770 | $625,085 | 0 | $0 | 0 | $0 |
| 2021-01 | 0 | $0 | 199,727 | $570,624 | 0 | $0 |
| 2020-01 | 0 | $0 | 113,630 | $517,014 | 0 | $0 |
| 2019-12 | 0 | $0 | 110,694 | $540,186 | 44,642 | $99,998 |
| 2019-11 | 0 | $0 | 11,667 | $61,251 | 11,667 | $33,250 |
| 2019-05 | 0 | $0 | 0 | $0 | 15,000 | $10,500 |
| 2017-12 | 0 | $0 | 0 | $0 | 60,000 | $163,800 |
| 2017-11 | 10,710 | $50,122 | 0 | $0 | 20,000 | $54,600 |
| 2017-06 | 0 | $0 | 0 | $0 | 60,000 | $291,000 |
| 2016-11 | 0 | $0 | 0 | $0 | 15,000 | $97,350 |
| 2016-04 | 0 | $0 | 0 | $0 | 45,000 | $225,450 |
| 2016-03 | 0 | $0 | 0 | $0 | 15,000 | $75,150 |
| 2015-11 | 0 | $0 | 153,333 | $1,968,795 | 153,333 | $352,665 |
| 2015-06 | 0 | $0 | 147,500 | $1,449,658 | 80,834 | $264,792 |
| 2015-02 | 1,440,000 | $12,600,000 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-09-01 | Boyle Kevin S. Sr. (Chief Executive Officer) | Sale | 68,014 | .14 | 9,521 |
| 2021-12-22 | De Groot Eleanor (EVP, Operations) | Sale | 20,132 | 1.27 | 25,567 |
| 2021-11-17 | Boyle Kevin S. Sr. (Chief Executive Officer) | Buy | 9,116 | 1.40 | 12,762 |
| 2021-11-16 | Boyle Kevin S. Sr. (Chief Executive Officer) | Buy | 884 | 1.40 | 1,237 |
| 2021-09-29 | Vieser Jaime (Director) | Buy | 100,000 | 1.91 | 191,000 |
| 2021-09-02 | Postma Robert W (Director) | Buy | 75,000 | 1.73 | 129,750 |
| 2021-09-02 | Hagen Heidi (Director) | Buy | 23,770 | 1.76 | 41,835 |
| 2021-09-01 | Weis Holger (Director) | Buy | 50,000 | 1.83 | 91,500 |
| 2021-09-01 | Huang James (Director) | Buy | 100,000 | 1.71 | 171,000 |
| 2021-01-08 | Buck Jill (EVP, GM Gene Therapy) | Sale | 27,894 | 3.12 | 87,029 |
| 2021-01-08 | Hadfield Robert (General Counsel and Secretary) | Sale | 26,500 | 3.12 | 82,680 |
| 2021-01-08 | Lafond Kevin G (SVP, Treasurer & CAO) | Sale | 18,020 | 3.09 | 55,681 |
| 2021-01-04 | De Groot Eleanor (EVP, GM Cell Therapy) | Sale | 21,620 | 2.72 | 58,806 |
| 2021-01-04 | Cooper Laurence James Neil (President and CEO) | Sale | 105,693 | 2.71 | 286,428 |
| 2020-01-02 | Buck Jill (EVP, GM Gene Therapy) | Sale | 27,923 | 4.55 | 127,049 |
| 2020-01-02 | De Groot Eleanor (EVP, GM Cell Therapy) | Sale | 24,890 | 4.55 | 113,249 |
| 2020-01-02 | Hadfield Robert (General Counsel and Secretary) | Sale | 16,853 | 4.55 | 76,681 |
| 2020-01-02 | Lafond Kevin G (SVP, Treasurer & CAO) | Sale | 21,570 | 4.55 | 98,143 |
| 2020-01-02 | Mauney David M Md (President) | Sale | 22,394 | 4.55 | 101,892 |
| 2019-12-30 | Cooper Laurence James Neil (Chief Executive Officer) | Sale | 110,694 | 4.88 | 540,186 |
| 2019-12-27 | Cooper Laurence James Neil (Chief Executive Officer) | Option Ex | 44,642 | 2.24 | 99,998 |
| 2019-11-26 | Lafond Kevin G (SVP, Treasurer & CAO) | Sale | 11,667 | 5.25 | 61,251 |
| 2019-11-26 | Lafond Kevin G (SVP, Treasurer & CAO) | Option Ex | 11,667 | 2.85 | 33,250 |
| 2019-05-07 | Cannon James Anthony (Director) | Option Ex | 15,000 | .70 | 10,500 |
| 2017-12-12 | Cannon James Anthony (Director) | Option Ex | 20,000 | 2.73 | 54,600 |
| 2017-12-11 | Fowler Wyche (Director) | Option Ex | 20,000 | 2.73 | 54,600 |
| 2017-12-08 | Weiser Michael (Director) | Option Ex | 20,000 | 2.73 | 54,600 |
| 2017-11-20 | Brennan Murray (Director) | Option Ex | 20,000 | 2.73 | 54,600 |
| 2017-11-08 | Cooper Laurence James Neil (Chief Executive Officer) | Buy | 6,440 | 4.68 | 30,139 |
| 2017-11-08 | Mauney David M Md (EVP and Chief Business Officer) | Buy | 4,270 | 4.68 | 19,983 |
| 2017-06-12 | Brennan Murray (Director) | Option Ex | 15,000 | 4.85 | 72,750 |
| 2017-06-12 | Cannon James Anthony (Director) | Option Ex | 15,000 | 4.85 | 72,750 |
| 2017-06-12 | Fowler Wyche (Director) | Option Ex | 15,000 | 4.85 | 72,750 |
| 2017-06-12 | Weiser Michael (Director) | Option Ex | 15,000 | 4.85 | 72,750 |
| 2016-11-25 | Brennan Murray (Director) | Option Ex | 15,000 | 6.49 | 97,350 |
| 2016-04-21 | Cannon James Anthony (Director) | Option Ex | 15,000 | 5.01 | 75,150 |
| 2016-04-19 | Weiser Michael (Director) | Option Ex | 15,000 | 5.01 | 75,150 |
| 2016-04-04 | Fowler Wyche (Director) | Option Ex | 15,000 | 5.01 | 75,150 |
| 2016-03-10 | Brennan Murray (Director) | Option Ex | 15,000 | 5.01 | 75,150 |
| 2015-11-19 | Belbel Caesar J (COO, CLO, and Secretary) | Sale | 153,333 | 12.84 | 1,968,795 |
| 2015-11-19 | Belbel Caesar J (COO, CLO, and Secretary) | Option Ex | 153,333 | 2.30 | 352,665 |
| 2015-06-09 | Lebel Francois (Executive Vice President R&D) | Sale | 50,000 | 10.12 | 505,999 |
| 2015-06-09 | Lebel Francois (Executive Vice President R&D) | Option Ex | 50,000 | 4.34 | 217,000 |
| 2015-06-04 | Brennan Murray (Director) | Sale | 5,837 | 9.55 | 55,743 |
| 2015-06-03 | Lafond Kevin G (Vice Pres., Treasurer, & CAO) | Sale | 57,500 | 9.67 | 555,852 |
| 2015-06-03 | Lafond Kevin G (Vice Pres., Treasurer, & CAO) | Option Ex | 30,834 | 1.55 | 47,792 |
| 2015-06-03 | Brennan Murray (Director) | Sale | 34,163 | 9.72 | 332,064 |
| 2015-02-09 | Intrexon Corp | Buy | 1,440,000 | 8.75 | 12,600,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of ZIOP listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Alaunos Therapeutics, Inc. (symbol ZIOP, CIK number 1107421) see the Securities and Exchange Commission (SEC) website.